1.1 Subscription and direct primary care models

A compliant subscription model generates $27,000 per month from subscriptions alone at $45 per patient across a panel of 600 patients. Subscription revenue goes to the practice; GPs keep all consultation fees. Evercare grew from approximately 2,000 patients in 2018 to over 100,000 by 2023, with plans for 60 clinics by 2030.

Cleanbill data identifies at least 98 medical centres offering bulk billing to non-concession adult patients subject to a membership or subscription fee, with monthly fees typically ranging from $20 to $65. Several also charge a separate annual or one-off administration fee. The compliance question under the Health Insurance Act 1973 (Cth) turns on whether the subscription is a condition of access to bulk-billed services. LHMU v MJA and subsequent ATO guidance establish that a subscription model is compliant where Medicare-eligible services are bulk-billed without requiring subscription membership.

The revenue arithmetic for the compliant version: at $45 per patient per month, a panel of 600 patients brings in $27,000 per month or $324,000 annually in subscription revenue, before consultation billings. This sits entirely outside MBS and is not subject to Medicare compliance.

1.2 BBPIP and the bulk billing decision

BBPIP adds 12.5% to MBS revenue for fully bulk-billing practices, split 50:50 between providers and practice. Government messaging has conflated the incentive with unconditional bulk billing rate increases, but BBPIP is conditional on full bulk billing of all eligible MBS services at the registered practice.

The structural choice for practice owners has sharpened. RSM’s February 2026 analysis noted that government messaging has created patient expectations of bulk billing as a norm in areas where it was previously uncommon. For practice owners, the decision now means comparing BBPIP gains with the revenue limits of bulk billing, considering patient demographics, payroll tax position and competitive context.

1.3 Chronic disease management: GPCCMP, Health Assessments and Home Medication Reviews

Chronic disease management items account for 10.49% of all MBS billings, up from 9.32% in 2022. Approximately 4.1 million Australians have two or more chronic conditions; this is the patient cohort that generates GPCCMP items.

The old items (GP Management Plans, Team Care Arrangements and their review items) were replaced by the GP Chronic Condition Management Plan (GPCCMP) and its review items in the 2025 budget. From 1 July 2025, preparing a GPCCMP or GPCCMP review combines what was previously billed separately as a GP Management Plan and Team Care Arrangement.

Patients registered with MyMedicare must access GPCCMP items through their registered practice, creating a direct financial incentive for practices to actively manage enrolment. The allied health referral elements remain a significant per-patient revenue driver through associated pathology, allied health and medication reviews.

Health assessments and Home Medication Reviews are two further Medicare-funded revenue streams in this category. Health assessments have four time tiers, and some of this time can be delegated to practice nurses or Aboriginal and Torres Strait Islander health workers. Eligible groups include: people aged 75 and older; type 2 diabetes risk evaluation (40–49 years); people aged 45–49 at risk of developing chronic disease; residents of residential aged care facilities; people with an intellectual disability; refugees and other humanitarian entrants; and veterans (one-off assessment).

The business opportunity relates not just to the rebate but to the ability to delegate tasks to the practice nurse, increasing the number of patients the GP can service during the same period. Home Medication Reviews (HMR) involve a GP referral to an accredited pharmacist who reviews the patient’s medications in their home and provides a report. The GP charges a review consultation from the MBS items, and the pharmacist charges the Commonwealth separately.

1.4 MyMedicare registration and financial benefits

80% of GP practices are registered for MyMedicare. As of March 2025, roughly 10% of the population had enrolled. That gap between practice registration and patient enrolment is the primary opportunity: practices that actively enrol patients unlock financial benefits that do not apply to non-enrolled patients.

MyMedicare enrolment unlocks four financial benefits: triple bulk billing incentives on longer telehealth consultations (Level C, D and E video items; Level C and D phone items); access to longer MBS-funded telephone consultation items (35+ and 60+ minutes); GPCCMP chronic disease management items tied to the enrolled practice from 1 July 2025; and GPACI eligibility at $430 per enrolled residential aged care patient per year.

From 1 July 2025, chronic condition management plan items are attached to the patient’s registered practice. A practice that has not actively enrolled its chronic disease patients will lose those items to whichever practice the patient subsequently registers with. GPACI compounds this: a practice interested in the aged care income stream cannot access it without MyMedicare registration for each eligible patient.

The enrolment gap has a specific cause. Only 33% of Medicare card-holding Australians had heard of MyMedicare in early 2025. The enrolment rate is low not because patients are refusing to enrol, but because most practices have not run an active enrolment process. As of March 2025, approximately 2.6 million patients were enrolled across 6,469 registered practices, averaging roughly 400 enrolled patients per practice, well below the population coverage of most practices.

1.5 Direct-to-consumer and platform telehealth

Platform telehealth has developed as a distinct revenue model operating largely outside Medicare fee-for-service. Three specific telehealth revenue streams warrant attention from practice owners.

Sexual and reproductive health telehealth

Twenty-four MBS items covering blood-borne virus, sexual and reproductive health services are permanently exempt from the existing clinical relationship (ECR) requirement. A GP can consult and treat a new patient via video or phone without a prior in-person relationship for these items. This creates a targeted telehealth stream that is not constrained by the ECR rules that limit most telehealth billing.

Condition-specific consumer platforms

Platforms including Mosh, Moshy and Pilot operate subscription-based models across weight loss, hair loss, skin and men’s health. These platforms contract GPs to provide telehealth consultations, with the platform handling patient acquisition and administration. Revenue per consultation varies by platform and condition category. GP participation is as a contracted provider; the platform carries patient relationship and compliance obligations.

Medicinal cannabis

The Australian medicinal cannabis sector reached $445.6 million in revenue in 2024–25, with 979,000 prescription applications approved by the TGA (up from 668,000 in 2023–24). The regulatory environment has tightened. AHPRA reported eight practitioners issuing more than 10,000 cannabis scripts in a single year, prompting formal investigation. Prescribing in this space requires current attention to AHPRA guidance on prescribing standards and advertising restrictions.

1.6 Employer and corporate wellness contracts

Employer-contracted GP services sit outside the Medicare rebate structure. Employers in construction, manufacturing, mining and retail pay above-MBS rates for on-site or reserved-access GP time. Contracts typically cover pre-employment medicals, occupational health assessments and dedicated access for staff.

GP locum rates in clinic settings run $1,600 to $3,000 per day; any corporate contract needs to price GP time against this benchmark. The employer case is straightforward: 60% of Australians delayed a GP visit in 2024 due to cost or unavailability. Employers understand this and some are willing to pay for access. The corporate wellness services industry generates approximately $333 million in annual revenue.

For independent practice owners, competing against a corporate operator with 200 locations and a dedicated employer contracts team is a realistic constraint. Corporate contracting works for practices with a specific sectoral advantage: proximity to a major employer, established occupational health credentials, or existing WorkCover panel relationships.

1.7 Medico-legal and insurance examination work

Independent medical examination (IME) work sits outside Medicare billing and generates revenue not subject to rebate caps. Victoria, NSW and Queensland set GP IME fees through gazetted fee schedules updated annually (WorkSafe Victoria, SIRA NSW, WorkCover Queensland). Reported fee ranges run $800 to $4,400 per report depending on complexity and jurisdiction.

Volume depends on subspecialty credibility (occupational medicine, musculoskeletal, psychiatry) and on established relationships with plaintiff and defendant legal firms, insurers and workers compensation agencies. Without an established referral network, entry is slow. With one, volume can be significant and is not subject to the patient throughput constraints of standard GP work.

1.8 Subspecialty revenue layers

Subspecialty layers sit alongside core general practice as discrete revenue streams. Each has its own credentialing pathway, capital and operating profile, regulatory envelope and commercial logic. The summary table below covers all eight subspecialties; individual sections follow.

1.8.1 Skin cancer medicine

Australia has the highest melanoma incidence in the world, with Queensland the highest age-standardised rate globally. More than 1.1 million GP encounters relate to skin conditions annually.

1.8.2 Women's health and contraception

Women aged 15 to 64 make up roughly half of the patient base in most Australian general practices, and clinical demand for women's health procedural skills has grown consistently since 2020.

1.8.3 Aesthetic medicine

The Australian medical aesthetics market was valued at $396.4 million in 2025 and is projected to reach $784.8 million by 2034.

1.8.4 GLP-1 and weight management

GLP-1 receptor agonist prescribing has reset the commercial landscape for GP weight management since 2023. Wegovy (semaglutide) and Mounjaro (tirzepatide) are TGA-approved for chronic weight management; neither is PBS-listed for obesity, meaning patients carry the full private script cost. Patient demand has run ahead of GP-side capacity to assess, prescribe and follow up.

1.8.5 Sports and musculoskeletal medicine

Sports and musculoskeletal work combines private fees, MBS consultation and procedure items, and WorkCover and TAC scheduled fees across several conditions in a high-volume primary care category.

1.8.7 Travel medicine

Travel medicine is private-fee dominant with limited MBS dependency: consultation, vaccines and destination-specific advice are all privately billable. Demand tracks international travel volumes, which rebuilt past pre-pandemic levels in 2024–25.

1.8.8 Occupational medicine

Occupational medicine generates contracted revenue from corporate accounts and workers compensation panels, providing volume predictability that core GP practice does not.

1.8.9 Mental health care

Focused Psychological Strategies (FPS) skills training enables GPs to bill higher-rebate Mental Health Treatment Plan (MHTP) items. Mental health is consistently the most commonly managed problem in Australian general practice.

1.9 Nurse and allied health integration

The Workforce Incentive Program (WIP) Practice Stream provides financial support for practices employing eligible health professionals including practice nurses, Aboriginal and Torres Strait Islander health practitioners, allied health professionals and mental health professionals. The maximum WIP payment is $137,375 per year, subject to a blended formula based on practice location, hours and staff mix.

The revenue rationale extends beyond the WIP. Practices with chronic disease management plans generate referral-linked allied health revenue through coordinated care arrangements. Practices with nurse-led chronic disease management programmes bill more GPCCMP items, more health assessments and more review consultations than those relying on GP time alone.

No peer-reviewed Australian study on the per-patient revenue uplift from nurse-led integration in general practice is available. The operational case is strong; the financial quantification is practice-specific.

1.10 General Practice in Aged Care Incentive (GPACI)

GPACI pays $430 per enrolled RACH patient per year, split between the GP ($300) and the practice ($130), delivered quarterly. Those payments are added to standard MBS billing for each visit. RACH patients are universally concession cardholders, attracting the full bulk-billing incentive uplift under BBPIP.

The minimum service requirement under GPACI (10 visits per patient per year, including two care planning items) is compatible with standard RACH GP service patterns. Rural loading increases the payment: 20% for MMM 3, 30% for MMM 4–5, 50% for MMM 6–7.

The constraint sits in the registration architecture. GPACI requires the practice, the GP and each enrolled patient to be registered with MyMedicare. Patient registration requires active enrolment by the resident or their representative. GPACI replaced the PIP GP Aged Care Access Incentive, which ceased 31 July 2024. Registration opened 1 July 2024.

1.11 Private health insurer entry into general practice

Section 126 of the Health Insurance Act 1973 (Cth) prohibits insurance contracts that cover medical expenses for a service where a Medicare benefit is payable. Section 121-10 of the Private Health Insurance Act 2007 (Cth) separately prevents insurers from paying benefits for services attracting a Medicare benefit. Private health insurers cannot cover standard GP consultations.

The practical effect: private health insurers cannot cover standard GP consultations. They can fund services not on the MBS schedule, including allied health where no Medicare benefit applies, and preventive health programs outside rebate scope. Both major insurers are now operating GP clinic networks at scale. Medibank's subsidiary Amplar Health received ACCC approval to acquire Myhealth Medical Group in 2024, adding 50 clinics. Bupa operates Bupa Dental and Medical in major cities. The ACCC's mandatory merger regime, effective 1 January 2026, applies to further acquisitions above threshold.

No peer-reviewed financial analysis of insurer-owned clinic effects on competition between independent and corporate practices is available. The competitive dynamic is observable in metropolitan markets where insurer clinics operate.

2.1 Structural barriers at a glance

2.2 Marketing consent requirements

Australian GP practices do not have a ready-made, legally clean channel for mass electronic marketing to their patient base. The Spam Act 2003 (Cth) requires express consent for commercial electronic messages. The Privacy Act 1988 (Cth) and APP 7 impose an additional layer: direct marketing using health information requires consent, and health information is sensitive information under the Act.

A practice wishing to communicate a new service model to existing patients must have obtained marketing consent at registration or through a subsequent explicit consent process. Most practices have not. The practical options are: obtain consent prospectively through a registration update process; use opt-in mechanisms in waiting rooms or patient portals; or limit electronic outreach to patients who have provided consent through a specific channel.

2.3 AHPRA advertising restrictions

The Health Practitioner Regulation National Law prohibits advertising that uses testimonials or purported testimonials about a regulated health service. This constrains patient review platforms, social media marketing and any content featuring patient outcomes or satisfaction statements.

The rules also prohibit unsubstantiated health outcome claims and claims creating unrealistic expectations. Advertising cosmetic procedures to individuals under 18 is prohibited. AHPRA's enforcement activity in aesthetic medicine has increased since 2023, with formal investigations of practitioners advertising prohibited content.

2.4 Non-contractual patient relationship

The standard GP-patient relationship is not contractual. A patient does not sign a service agreement. Transitioning a patient panel to a subscription or mixed-billing model requires each patient to consent to the new arrangement individually, and patients can choose not to. For MyMedicare-enrolled patients, enrolment is voluntary and can be changed. Patient loyalty data suggests 68% prefer to stay with their regular GP when a choice is available, but this figure reflects preference, not contractual obligation.

2.5 Patient price sensitivity and bulk billing expectations

The 2025 bulk billing expansion has materially altered patient expectations in metropolitan areas. RSM noted in February 2026 that government messaging has created patient expectations of bulk billing as a norm in areas where it was previously uncommon. Lower-SES areas, concession cardholders and children under 16 now attract full bulk billing uplift, making private billing economically unjustifiable for those patient cohorts.

2.6 GP workforce shortage as a constraint

The GP shortfall constrains every revenue model requiring additional GP time, training or patient capacity (see section 5 for workforce economics in full). With 69% of GPs reporting burnout in 2025 and 32% planning to retire within five years, the ability to recruit additional GP capacity for new service lines cannot be assumed. Revenue models that require additional GP FTE to generate incremental income are constrained at source.

2.7 Accreditation and compliance overhead

RACGP accreditation under the Standards for General Practices involves ongoing documentation, audit and compliance obligations. Each new service stream adds documentation requirements, risk management obligations and potentially additional accreditation standards. For small practices without administrative support, compliance overhead is a genuine constraint on service expansion.

2.8 Corporate ownership and independent practice competitiveness

The top eight corporate and group operators control approximately 39% of group-operated practices and related facilities. For an independent owner seeking to enter employer contracting, the competitive constraint is real: a corporate operator can offer an employer guaranteed coverage across multiple locations, dedicated account management and integrated billing, none of which an independent practice can match. Independent practices competing in this space need a specific sector advantage: proximity, established relationships or subspecialty credentials.

3.1 US direct primary care

As of early 2026, approximately 2,827 DPC offices operate across the United States, up from approximately 1,200 in 2020. DPC Frontier reports practices maintaining panels of approximately 600 patients achieve 66% fewer ED visits and a 20% reduction in specialist referrals compared to fee-for-service equivalents.

Structural transferability to Australia is limited: US DPC practices opt out of all insurance billing. In Australia, even subscription-model practices bulk-bill through Medicare for eligible services. The compliant Australian equivalent is a hybrid: subscription fee plus Medicare billing. True opt-out is not a viable mass-market model under current legislation.

3.2 UK primary care networks

Primary care networks (PCNs) are groups of GP practices covering populations of approximately 30,000–50,000 patients. Over 99% of English GP practices have joined one; approximately 1,250 PCNs operate across England. PCN funding enables practices to employ multidisciplinary roles (pharmacists, physiotherapists, social prescribers, mental health workers) through additional PCN payments, reducing the individual practice's cost of allied health integration.

The comparison with Australia: PCNs are a geographically organised collaboration model funded through a capitation-adjacent mechanism tied to enrolled patient populations. MyMedicare introduces a similar logic at the patient level, but without the practice collaboration or dedicated multidisciplinary workforce funding that PCNs provide. The WIP Practice Stream is the closest Australian equivalent, but operates at a fraction of PCN funding levels.

3.3 New Zealand capitation model

New Zealand's Primary Health Organisations (PHOs) are paid based on enrolled patients, not consultations. A 2019 BMJ Open study found higher per-patient costs and similar or better health outcomes compared to fee-for-service models for chronic disease management.

The feature most relevant to Australia: MyMedicare introduces a partial capitation logic, with practices receiving additional payments per enrolled patient (GPACI, enhanced telehealth, GPCCMP lock-in). The constraint is scale. In NZ, PHO enrolment is the primary funding mechanism. In Australia, MyMedicare is a voluntary supplement to a fee-for-service base. The incentive architecture points toward capitation without the funding volume that makes it the dominant model.

4.1 Practice acquisition and consolidation

Australian general practice is in an accelerating phase of consolidation. Of approximately 7,135 accredited practices, the top eight corporate and group operators control approximately 39% of group-operated practices and related facilities. Private equity investment in Australian health care reached $4.5 billion in acquisitions during 2022, with general practice a primary target.

The RACGP's Health of the Nation 2024 report found nearly one in four practice owners (24%) intended to sell within 12 months of the survey. That supply pipeline, combined with corporate and PE buyer demand, sustained high transaction volume through 2023–25.

4.2 GP practice valuation

GP practices are typically valued using an EBITDA multiple. Clinch Group's September 2025 analysis found average EBIT at 14.4% of revenue, lower than the broader healthcare sector. The prevailing benchmark: 3x to 5x EBITDA for standard practices sold to individual buyers or smaller groups. At the corporate end, 5x to 8x EBITDA for practices with strong billings, good location, and low owner-dependence.

The distinction between personal goodwill and commercial goodwill matters. Practices where the principal generates a large proportion of billings and has deep personal relationships with patients trade at lower multiples than those with distributed billing across multiple GPs and a transferable patient base. Subcontracting GPs now typically receive 65–75% of billings (up from 60–65%), meaning only 25–35% flows to practice revenue. This compression affects EBITDA and therefore sale multiples.

4.3 Due diligence beyond financials

Dimensions buyers commonly under-weigh:

• Revenue sustainability: whether billing patterns and CDM volumes would survive audit scrutiny.
• Payroll tax position: settled differently by state (see section 5.5).
• Lease security: 5+5 year option lease is a baseline for premium multiples.
• GP service agreements: written, compliant contractor agreements required for payroll tax exemption.
• Owner-dependence: proportion of billings attributable to the selling principal.
• Accreditation: RACGP Standards status affects PIP eligibility.

4.4 ACCC mandatory merger regime

From 1 January 2026, Australia moved to a mandatory and suspensory merger control regime. Acquisitions meeting thresholds must be notified to the ACCC before completion. Two thresholds apply. First: combined Australian revenue of $200 million or more and target revenue of $50 million or more. Second: a cumulative acquisition threshold where the acquirer has made three or more acquisitions in the same or a similar sector over three years.

For major operators including Amplar Health and PE platforms above $500 million, the three-year cumulative threshold means most individual practice acquisitions now require notification. Mid-tier operators below $500 million face more limited impact: most individual practice acquisitions at typical valuations do not clear the first threshold. The regime adds time and cost to transactions at scale.

4.5 Corporate ownership and quality of care

A 2021 MJA Perspective identified four potential effects of corporatisation: reduced access where small practices consolidate; reduced quality where profit pressure alters clinical decisions; reduced choice where local market concentration increases; and reduced GP autonomy. The evidence base for these effects in the Australian context remains limited. The RACGP has called for regulatory oversight of GP corporate concentration; no specific legislative response has followed to date.

5.1 GP shortage and revenue constraints

A practice that cannot attract or retain GPs cannot bill. High turnover loses continuity-linked revenue: CDM plan reviews, MyMedicare-enrolled patient billings and GPACI payments are all attached to the patient–GP relationship. Australia's current GP shortfall is estimated at 3,010–3,620 FTE. The RACGP National Workforce Strategy 2025–30 projects a shortfall of 6,400 FTE by 2040 if current training and distribution patterns continue.

5.2 GP remuneration models

The standard structure: VR GPs receive approximately 65–70% of billings as subcontractors; non-VR GPs 60–65%. Competition for VR GPs in metropolitan markets has pushed rates above 70% in some practices. Mixed-billing and private-billing practices offer GPs higher gross billings per consultation. The average Level B fee has increased since the 2023 bulk billing expansion; the percentage split determines whether that increase reaches the GP.

Evercare's subscription model is partly a GP attraction mechanism: GPs retain 100% of consultation billings, with practice revenue coming entirely from subscriptions. The BBPIP 50:50 split between GPs and practices has drawn RACGP concern. In bulk billing practices, economics have typically seen GPs receive a higher percentage; the 50:50 split formalises a practice revenue share that some GPs view as unfavourable.

5.3 Government workforce recruitment incentives

The government has committed $204.8 million for salary incentives for junior doctors to specialise in general practice, and $110.7 million for scholarships and incentives to attract GPs to rural and remote areas. The WIP Doctor Stream provides payments to GPs in MM 3–7 areas based on hours, location and rurality loading.

The GP Training Incentive Payment provides $30,000 for junior doctors commencing rural GP training rotations. Practices in eligible locations that take registrars can access this payment as part of the broader teaching and training ecosystem.

5.4 Practice design and GP retention

Financial remuneration is necessary but not sufficient. RACGP research found burnout common in GP supervisors and associated with administrative load, not clinical load. AI scribe adoption (40% of GPs by November 2025) recovers approximately 4 minutes of documentation per consultation, equivalent to approximately 2 clinical sessions per week for a full-time GP. Practices that have adopted scribes can present this as a measurable working condition improvement in recruitment conversations.

Doctor ownership is a documented recruitment differentiator: GPs cite clinical autonomy, governance participation and investment in the practice as factors in choosing a practice over a corporate employer. Mixed-ownership models and partnership tracks are retention mechanisms independent of remuneration percentage.

5.5 Payroll tax by state

The payroll tax position diverges materially across states following the 2023–24 relief and amnesty period.

Queensland: Blanket exemption covering all GP wages (contractor and employee) regardless of billing model, effective 1 December 2024. Estimated cost: $538 million over five years.

Victoria: Proportional exemption from 1 July 2025, calculated by reference to the practice's bulk-billed revenue share. Practices with 75% or more bulk billing receive a full exemption; below that, a partial exemption applies.

New South Wales: Retrospective exemption for unpaid payroll tax on contractor GP wages before 4 September 2024 (no refunds). From that date, practices with bulk billing above 70% receive exemption. Below 70%, standard payroll tax rates apply to GP contractor payments.

South Australia: RevenueSA has issued post-Thomas and Naaz contractor guidance and provides a targeted bulk-billing-related relief. Independent advice recommended for mixed-billing practices.

Western Australia: WA has not adopted the contractor reassessment position taken in eastern states. RevenueWA continues to apply standard payroll tax principles.

Tasmania: State Revenue Office Tasmania has indicated that genuine independent contractor relationships in medical practice are outside payroll tax. The position is based on contractual substance, not a blanket GP exemption.

Australian Capital Territory: ACT Revenue Office provides a targeted exemption for bulk-billed GP consultations. Scope and threshold require independent verification.

Northern Territory: NT applies standard payroll tax principles without sector-specific GP rulings. Practices operate under standard contractor-versus-employee assessment.

For mixed-billing practices above threshold, exposure runs to approximately 4.85% of contractor GP payments in Victoria and NSW where exemptions do not fully apply. State-specific advice is required; the position in each jurisdiction has moved since 2023 and continues to evolve.

5.6 Single Employer Model for GP registrars

The Single Employer Model (SEM) restructures GP registrar employment so a state health service, rather than the training practice, becomes the employer of record. The SEM is a phased trial across five states running until 31 December 2028 (no trials in WA, NT or ACT). The cost change for practices is direct: the practice no longer pays registrar wages. In Tasmania, the practice retains a financial contribution obligation; in other SEM states, the health service bears the full employment cost.

Commonwealth commitment: $6.4 million through 2027–28 for expansion and evaluation, plus $7.97 million for Tasmania. The workforce rationale is to remove the financial barrier that prevents rural and regional practices from taking registrars. The commercial implication for training practices: reduced payroll and super obligations during the registrar's placement, offset by a reduction in the administrative control over the registrar's rostering.

6.1 MBS indexation and the real value of GP fees

From 1995 to 2022, MBS items received average annual indexation of 1.1%, against CPI of 2.42% and Average Weekly Earnings growth of 3.5%. The 2023 Strengthening Medicare package committed to annual indexation aligned to wage growth; the first indexed increase applied in November 2023. Whether this commitment is maintained across budget cycles is the key variable for any revenue model that depends on MBS rebate levels.

6.2 Strengthening Medicare Taskforce implementation

The Taskforce reported February 2023 with four priority areas. The government committed $750 million through the Strengthening Medicare Fund. Implemented measures include: expanded bulk billing incentive (November 2023, extended to all Australians from November 2025); Medicare Urgent Care Clinics ($657.9 million committed for 137 UCCs); MyMedicare voluntary patient registration; and longer telehealth items for enrolled patients. Pending: Scope of Practice reforms, Multidisciplinary Team funding model.

6.3 GP workforce supply and distribution

113 FTE GPs per 100,000 population in 2024, up from 110 in 2023. Workforce headcount: 40,375 GPs (32,557 VR, 1,618 non-VR, 6,200 registrars in training). Distribution remains the constraint: supply is concentrated in major cities; rural and remote areas face structural shortfalls that incentives have not resolved.

6.4 Patient demand patterns

81.4% of Australians (approximately 20.7 million people) had at least one long-term health condition in 2022 (ABS). 9.7 million Australians had two or more. An older, more chronically ill population requires more GP time, more care coordination and more allied health integration. Chronic disease management is the structural growth category in GP revenue; the question for practice owners is whether their workforce and systems can service growing demand.

6.5 AI-assisted clinical tools

As of November 2025, approximately 40% of surveyed GPs were using AI scribes, up from 22% in August 2024. Avant data shows 75% of users reported improved work-life balance; 73% said clinical quality improved or stayed the same. From August 2025, the TGA began classifying AI scribes that provide diagnostic suggestions or clinical decision support as medical devices requiring registration. Scribes that only transcribe and summarise remain outside the medical device classification.

AI scribes can reduce documentation time by up to 40% (2025 AJGP). Saving 4 minutes per patient across 30 consultations equals 2 hours of recovered time daily. A small Australian survey found GPs often returned saved time to patients through longer consultations rather than increasing throughput. No published Australian study quantifies the billing revenue impact.

6.6 Medicare urgent care clinics

The government committed $657.9 million to 137 UCCs. The 87 already operating delivered over 2.5 million visits since 2023. Each UCC presentation costs $246.50, more than five times a standard GP consult at approximately $44. Only 68% of UCC presentations included a face-to-face clinical assessment; 32% were nurse-led triage only.

UCCs create competitive pressure on nearby GP practices for walk-in, acute and after-hours presentations. Several contracts have been awarded to existing practices and GP corporate operators, creating a dual dynamic: some practices benefit from UCC contracts; others face diversion of their after-hours and acute patient base.